Correlation Between Hookipa Pharma and Apogee Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hookipa Pharma and Apogee Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hookipa Pharma and Apogee Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hookipa Pharma and Apogee Therapeutics, Common, you can compare the effects of market volatilities on Hookipa Pharma and Apogee Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hookipa Pharma with a short position of Apogee Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hookipa Pharma and Apogee Therapeutics,.

Diversification Opportunities for Hookipa Pharma and Apogee Therapeutics,

0.88
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Hookipa and Apogee is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Hookipa Pharma and Apogee Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apogee Therapeutics, and Hookipa Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hookipa Pharma are associated (or correlated) with Apogee Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apogee Therapeutics, has no effect on the direction of Hookipa Pharma i.e., Hookipa Pharma and Apogee Therapeutics, go up and down completely randomly.

Pair Corralation between Hookipa Pharma and Apogee Therapeutics,

Given the investment horizon of 90 days Hookipa Pharma is expected to under-perform the Apogee Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Hookipa Pharma is 1.23 times less risky than Apogee Therapeutics,. The stock trades about -0.22 of its potential returns per unit of risk. The Apogee Therapeutics, Common is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  4,396  in Apogee Therapeutics, Common on September 27, 2024 and sell it today you would earn a total of  336.00  from holding Apogee Therapeutics, Common or generate 7.64% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Hookipa Pharma  vs.  Apogee Therapeutics, Common

 Performance 
       Timeline  
Hookipa Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Apogee Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Hookipa Pharma and Apogee Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hookipa Pharma and Apogee Therapeutics,

The main advantage of trading using opposite Hookipa Pharma and Apogee Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hookipa Pharma position performs unexpectedly, Apogee Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apogee Therapeutics, will offset losses from the drop in Apogee Therapeutics,'s long position.
The idea behind Hookipa Pharma and Apogee Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Managers
Screen money managers from public funds and ETFs managed around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance